A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E2 in Patients With Barrett's Esophagus
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background & Aims Proton pump inhibitors (PPIs) and nonsteroidal anti-inflammatory drugs might prevent esophageal adenocarcinoma in patients with Barrett’s esophagus (BE), but there are limited data from clinical trials to support this concept. We conducted a randomized, double-blind, placebo-controlled phase II trial to assess the effects of the combination of aspirin (3 different doses) and esomeprazole on tissue concentrations of prostaglandin E2 (PGE2) in patients with BE with no dysplasia or low-grade dysplasia. Methods Participants were recruited through the multi-center Cancer Prevention Network and randomly assigned to groups that were given esomeprazole (40 mg, twice daily) in combination with an aspirin placebo (once daily) (Arm A; n=42), with 81 mg aspirin (once daily) (Arm B; n=63), or with 325 mg aspirin (once daily) (Arm C; n=63) for 28 days. We collected esophageal biopsies before and after the intervention period, to determine the absolute change in mean concentrations of PGE2 (the primary endpoint). Results Based on data from 114 patients, baseline characteristics were similar among groups. The absolute mean tissue concentrations of PGE2 was reduced by 67.6±229.68 pg/mL in Arm A, was reduced by 123.9±284.0 pg/mL in Arm B (P=.10 vs Arm A), and was reduced by 174.9 ±263.62 pg/mL in Arm C (P=.02 vs Arm A). Conclusions In combination with esomeprazole, short-term administration of higher doses of aspirin, but not lower doses or no aspirin, significantly reduced tissue concentrations of PGE2 patients with BE with either no dysplasia or low-grade dysplasia. These data support further evaluation of higher doses of aspirin and esomeprazole to prevent esophageal adenocarcinoma in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus
Nguyen, D. M., El-Serag, H. B., Henderson, L., Stein, D., Bhattacharyya, A., & Sampliner, R. E. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.001 · Cited by 159
Cited by
Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline
Shaheen, N. J., Falk, G. W., Iyer, P. G., Souza, R. F., Yadlapati, R. H., Sauer, B. G., & Wani, S. (2022) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001680 · Cited by 510
Self-citationDrug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Recent developments in esophageal adenocarcinoma
Lagergren, J., & Lagergren, P. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21185 · Cited by 309
Singh, S., Garg, S. K., Singh, P. P., Iyer, P. G., & El-Serag, H. B. (2014) · Gut · doi:10.1136/gutjnl-2013-305997 · Cited by 298
Chemopreventive strategies in hepatocellular carcinoma
Singh, S., Singh, P. P., Roberts, L. R., & Sanchez, W. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.143 · Cited by 273
Le-Rademacher, J., Hillman, S. L., Meyers, J., Loprinzi, C. L., Limburg, P. J., & Mandrekar, S. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx043 · Cited by 24
“Similar to the pattern observed in the symptom intervention trials described earlier, except for the aspirin 81mg arm of the MAYO 04-4-01 trial [11], the possibly related category accounts for 70–100% of all AEs classified as related to the intervention (Figure 1).”
BackgroundResultSelf-citation
Metadata
- Authors
- Falk, G. W., Buttar, N. S., Foster, N. R., Ziegler, K. L. A., DeMars, C. J., Romero, Y., Marcon, N. E., Schnell, T., Corley, D. A., Sharma, P., Cruz–Correa, M. R., Hur, C., Fleischer, D. E., Chak, A., DeVault, K. R., Weinberg, D. S., Della'Zanna, G., Richmond, E., Smyrk, T. C., Mandrekar, S. J., & Limburg, P. J.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 143
- Issue
- 4
- Pages
- 917-926.e1
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2004826442
- Cited by
- 64
- References
- 4
- FWCI
- 8.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.